ABT · 10-Q · 2026Q3 · Full report

DOJ Infant Formula Investigation

ABBOTT LABORATORIES · 2026-11-04 · Importance 47 · Surprise 60 · In source text

Abbott resolved investigations by the U.S. Department of Justice and complaints in September 2026 concerning its U.S. manufacturing of powdered infant formula. The DOJ and several states had partially intervened in a civil qui tam lawsuit alleging violations of federal and state laws, including the Federal False Claims Act. Abbott paid approximately $[amount not stated in the provided text], plus attorneys’ fees and accrued interest, to resolve all claims; the settlement was not a finding of fault or liability, and the filing states no evidence was found that its products caused the illnesses or deaths prompting the 2022 voluntary recall.

Key facts

• In September 2026, Abbott reached an agreement to resolve DOJ investigations and related complaints concerning its U.S. manufacturing of powdered infant formula products, agreeing to pay an amount plus attorneys’ fees and accrued interest. source
• Abbott’s DOJ settlement did not represent a finding of fault or liability, and no evidence was found that Abbott infant formula products caused the illnesses or deaths that prompted its voluntary recall in 2022. source

Impact estimates